| HOME >> MEDICINE >> TECHNOLOGY |
Pharmacopeia Advances and Expands Internal Pipeline as DARA Program Enters
Phase 2 Clinical Development and New SARM Program is Added
PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP) today announced results for the quarter and nine months ended September 30, 2007, and highlighted several important developments in its therapeutic programs and corporate milestones achieved since the beginning of the quarter.
During the third quarter of 2007:
-- Pharmacopeia announced the initiation of a Phase 2a hypertension
clinical trial for PS433540, an unpartnered product candidate from its
DARA program, that is both an angiotensin receptor blocker (ARB) and an
endothelin receptor antagonist (ERA). The trial was initiated less
than one year after IND submission and approximately six months ahead
of schedule.
Also during the quarter, the company announced positive results from
multiple Phase 1 clinical studies for PS433540. These Phase 1 findings
included:
-- PS433540 demonstrated its ability to block the increase in blood
pressure induced by administration of angiotensin II (AII) to
healthy volunteers. Numerous similar studies with other agents that
block the renin-angiotensin system support that this result is a
strong indication that PS433540 can be expected to lower blood
pressure in hypertensive patients. This Phase 1 study showed that
all doses of PS433540, compared with placebo, produced a
statistically significant (p<0.01) inhibition of the expected AII-
induced increase in blood pressure. Additionally, the findings
showed that the 250 mg and 500 mg doses of PS433540 were at least as
effective in blocking the AII response as irbesartan, a leading
angiotensin receptor blocker that is approved for th
'/>"/>
| SOURCE Pharmacopeia Copyright©2007 PR Newswire. All rights reserved |